Cargando…
Dysregulation of the TOX-RUNX3 pathway in cutaneous T-cell lymphoma
Studies have examined gene expression changes in Sézary syndrome (SS), but disease pathogenesis remains largely unknown, and diagnosis and treatment are difficult. TOX is a transcription factor involved in CD4+ T-cell development with downstream effects on RUNX3, a known tumor suppressor gene. We so...
Autores principales: | Dulmage, Brittany O., Akilov, Oleg, Vu, John R., Falo, Louis D., Geskin, Larisa J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6517103/ https://www.ncbi.nlm.nih.gov/pubmed/31139323 http://dx.doi.org/10.18632/oncotarget.5742 |
Ejemplares similares
-
TOX expression in cutaneous B-cell lymphomas
por: Schrader, Anne M. R., et al.
Publicado: (2016) -
United States Cutaneous Lymphoma Consortium recommendations for treatment of cutaneous lymphomas during the COVID-19 pandemic
por: Zic, John A., et al.
Publicado: (2020) -
The PROVe Study: US Real-World Experience with Chlormethine/Mechlorethamine Gel in Combination with Other Therapies for Patients with Mycosis Fungoides Cutaneous T-Cell Lymphoma
por: Kim, Ellen J., et al.
Publicado: (2021) -
Pyoderma gangrenosum in a patient with cutaneous T-cell lymphoma
por: Tang, Randy, et al.
Publicado: (2015) -
International Cutaneous Lymphomas Pandemic Section (ICLYPS) analysis of CTCL outcomes during COVID-19
por: Geskin, Larisa J, et al.
Publicado: (2021)